Inocucor raises $38.8 mln in TPG ART-led Series B financing

Inocucor Technologies Inc, a Montréal agricultural biotechnology company, has raised $38.8 million in the initial close of its Series B financing. The round was led by TPG ART, a late-stage venture capital fund of U.S. alternative assets firm TPG. It was joined by existing investors Cycle Capital Management and Desjardins Innovatech, as well as Closed Loop Capital. With the round, TPG's Geoff Duyk joined the board. Founded in 2007, Inocucor develops sustainable biological inputs to improve crop yields, shorten growing periods and create healthier, more resilient soils. The funds raised will support opening a U.S. office, increasing productive capacity and new hires.

CanadaNorth AmericaBriefs